All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
BCL-2 is an oncogene that promotes leukemogenesis by blocking programmed cell death. BCL-2 protein activation is downstream of multiple cellular pathways, including the IL-7 receptor, which is described to be mutated in specific ALL subtypes. Therefore, BCL-2 inhibitors like venetoclax are being investigated in ALL.